IBRX ImmunityBio Inc

Price (delayed)

$14.28

Market cap

$5.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$5.76B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
The company's gross profit has surged by 106% QoQ and by 13% YoY
ImmunityBio's revenue has surged by 106% QoQ and by 13% YoY
ImmunityBio's net income has shrunk by 81% YoY and by 66% QoQ
ImmunityBio's quick ratio has plunged by 62% YoY and by 26% from the previous quarter

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
383.91M
Market cap
$5.48B
Enterprise value
$5.76B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
23,867.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25,137.52
Earnings
Revenue
$229,000
EBIT
-$150.4M
EBITDA
-$136.19M
Free cash flow
-$127.9M
Per share
EPS
-$0.91
Free cash flow per share
-$0.33
Book value per share
-$1.7
Revenue per share
$0
TBVPS
$0.54
Balance sheet
Total assets
$209.43M
Total liabilities
$394.76M
Debt
$319M
Equity
-$185.79M
Working capital
$19.71M
Liquidity
Debt to equity
-1.72
Current ratio
1.25
Quick ratio
1.07
Net debt/EBITDA
-2.01
Margins
EBITDA margin
-59,470.7%
Gross margin
100%
Net margin
-67,080.3%
Operating margin
-69,565.1%
Efficiency
Return on assets
-76.1%
Return on equity
-4,845.9%
Return on invested capital
-58.4%
Return on capital employed
-116.1%
Return on sales
-65,677.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
-1.11%
1 week
-7.15%
1 month
-5.62%
1 year
N/A
YTD
N/A
QTD
-39.85%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$229,000
Gross profit
$229,000
Operating income
-$159.3M
Net income
-$153.61M
Gross margin
100%
Net margin
-67,080.3%
The company's gross profit has surged by 106% QoQ and by 13% YoY
ImmunityBio's revenue has surged by 106% QoQ and by 13% YoY
IBRX's operating income has dropped by 85% year-on-year and by 74% since the previous quarter
ImmunityBio's net income has shrunk by 81% YoY and by 66% QoQ

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
23,867.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25,137.52
ImmunityBio's EPS has shrunk by 54% YoY and by 2.2% QoQ
ImmunityBio's equity has shrunk by 55% QoQ
The P/S is 166% more than the 5-year quarterly average of 8956.0 and 55% more than the last 4 quarters average of 15422.8
ImmunityBio's revenue has surged by 106% QoQ and by 13% YoY

Efficiency

How efficient is ImmunityBio business performance
ImmunityBio's return on sales has shrunk by 60% YoY but it has increased by 21% QoQ
IBRX's return on assets is down by 49% since the previous quarter and by 36% year-on-year
The company's return on invested capital fell by 16% QoQ but it rose by 6% YoY

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 47% less than the total liabilities
The total assets has soared by 65% YoY but it has contracted by 5% from the previous quarter
ImmunityBio's quick ratio has plunged by 62% YoY and by 26% from the previous quarter
ImmunityBio's equity has shrunk by 55% QoQ
The company's debt to equity rose by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.